SG10201610193RA - Chimeric factor viii polypeptides and uses thereof - Google Patents
Chimeric factor viii polypeptides and uses thereofInfo
- Publication number
- SG10201610193RA SG10201610193RA SG10201610193RA SG10201610193RA SG10201610193RA SG 10201610193R A SG10201610193R A SG 10201610193RA SG 10201610193R A SG10201610193R A SG 10201610193RA SG 10201610193R A SG10201610193R A SG 10201610193RA SG 10201610193R A SG10201610193R A SG 10201610193RA
- Authority
- SG
- Singapore
- Prior art keywords
- factor viii
- chimeric factor
- viii polypeptides
- polypeptides
- chimeric
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261586099P | 2012-01-12 | 2012-01-12 | |
US201261586654P | 2012-01-13 | 2012-01-13 | |
US201261667901P | 2012-07-03 | 2012-07-03 | |
US201261734954P | 2012-12-07 | 2012-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201610193RA true SG10201610193RA (en) | 2017-01-27 |
Family
ID=48781968
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201403764XA SG11201403764XA (en) | 2012-01-12 | 2013-01-12 | Chimeric factor viii polypeptides and uses thereof |
SG10201610193RA SG10201610193RA (en) | 2012-01-12 | 2013-01-12 | Chimeric factor viii polypeptides and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201403764XA SG11201403764XA (en) | 2012-01-12 | 2013-01-12 | Chimeric factor viii polypeptides and uses thereof |
Country Status (29)
Country | Link |
---|---|
US (2) | US11370827B2 (en) |
EP (2) | EP2804623B1 (en) |
JP (4) | JP6255630B2 (en) |
KR (1) | KR102212098B1 (en) |
CN (4) | CN111499761A (en) |
AU (2) | AU2016202875B2 (en) |
BR (1) | BR112014017165B1 (en) |
CA (1) | CA2863328A1 (en) |
CO (1) | CO7010788A2 (en) |
CY (1) | CY1122509T1 (en) |
DK (1) | DK2804623T3 (en) |
EA (2) | EA028309B1 (en) |
ES (1) | ES2753124T3 (en) |
HK (1) | HK1202799A1 (en) |
HR (1) | HRP20191920T1 (en) |
HU (1) | HUE046396T2 (en) |
IL (2) | IL233463B (en) |
LT (1) | LT2804623T (en) |
MX (1) | MX357403B (en) |
MY (1) | MY201293A (en) |
NZ (1) | NZ626945A (en) |
PH (2) | PH12014501602B1 (en) |
PL (1) | PL2804623T3 (en) |
PT (1) | PT2804623T (en) |
RS (1) | RS59670B1 (en) |
SG (2) | SG11201403764XA (en) |
SI (1) | SI2804623T1 (en) |
TW (3) | TWI727187B (en) |
WO (1) | WO2013106787A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100256062A1 (en) | 2004-12-06 | 2010-10-07 | Howard Tommy E | Allelic Variants of Human Factor VIII |
ES2531464T3 (en) | 2008-06-24 | 2015-03-16 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or its complexes with prolonged in vivo half-life |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
US11370827B2 (en) | 2012-01-12 | 2022-06-28 | Bioverativ Therapeutics Inc. | Chimeric factor VIII polypeptides and uses thereof |
EP3564260B1 (en) | 2012-02-15 | 2022-10-19 | Bioverativ Therapeutics Inc. | Factor viii compositions and methods of making and using same |
DK2822577T3 (en) | 2012-02-15 | 2019-04-01 | Bioverativ Therapeutics Inc | RECOMBINANT FACTOR VIII PROTEINS |
US10287564B2 (en) | 2012-06-08 | 2019-05-14 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
WO2013185114A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
EP3404105A1 (en) * | 2012-07-06 | 2018-11-21 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
JP6603128B2 (en) | 2012-07-11 | 2019-11-06 | バイオベラティブ セラピューティクス インコーポレイテッド | Complex of factor VIII with XTEN and von Willebrand factor protein and uses thereof |
EP2928303A4 (en) | 2012-12-07 | 2016-07-13 | Haplomics Inc | Factor viii mutation repair and tolerance induction |
HUE053136T2 (en) | 2013-02-15 | 2021-06-28 | Bioverativ Therapeutics Inc | Optimized factor viii gene |
US10588949B2 (en) | 2013-03-15 | 2020-03-17 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
WO2014210547A1 (en) * | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
IL297611A (en) * | 2013-06-28 | 2022-12-01 | Bioverativ Therapeutics Inc | Thrombin cleavable linker with xten and its uses thereof |
EP3875106A1 (en) * | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
TWI667255B (en) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | Factor viii-xten fusions and uses thereof |
US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
MY192481A (en) * | 2014-01-10 | 2022-08-23 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
DK3164150T3 (en) * | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | MODIFIED BY WILLEBRAND FACTOR |
US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
DK3297656T3 (en) | 2015-05-22 | 2020-03-09 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for the treatment of haemophilia |
US10772936B2 (en) | 2015-05-22 | 2020-09-15 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
EP3331608A4 (en) | 2015-08-03 | 2019-05-01 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
US10596232B2 (en) | 2015-08-12 | 2020-03-24 | Cell Machines, Inc. | Methods and compositions related to long half-life coagulation complexes |
CN115141836A (en) | 2015-10-28 | 2022-10-04 | 桑格摩生物治疗股份有限公司 | Liver-specific constructs, factor VIII expression cassettes, and methods of use thereof |
SG10202106307UA (en) | 2015-11-13 | 2021-07-29 | Takeda Pharmaceuticals Co | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
WO2017112895A1 (en) * | 2015-12-23 | 2017-06-29 | Haplomics, Inc. | F8 gene repair |
AU2017204955B2 (en) | 2016-01-07 | 2021-04-01 | CSL Behring Lengnau AG | Mutated truncated von Willebrand Factor |
HUE059941T2 (en) | 2016-02-01 | 2023-01-28 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
CA3014921A1 (en) * | 2016-02-16 | 2017-08-24 | Research Development Foundation | Sortase-modified molecules and uses thereof |
JP2019522962A (en) * | 2016-05-20 | 2019-08-22 | オクタファルマ アクチェン ゲゼルシャフト | Glycosylated VWF fusion protein with improved pharmacokinetics |
JP7235511B2 (en) * | 2016-06-24 | 2023-03-08 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | Recombinant single-chain FVIII and chemical conjugates thereof |
WO2017222337A1 (en) * | 2016-06-24 | 2017-12-28 | 재단법인 목암생명과학연구소 | Chimera protein comprising fviii and vwf factors, and use thereof |
KR20190085021A (en) | 2016-11-11 | 2019-07-17 | 체에스엘 베링 렝나우 아게 | A cut von Willebrand factor polypeptide to treat hemophilia |
TW201828974A (en) | 2016-11-11 | 2018-08-16 | 瑞士商Csl貝林重組技能公司 | Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
EP3548063A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
US20190381149A1 (en) | 2016-12-02 | 2019-12-19 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
CN118184797A (en) * | 2017-02-27 | 2024-06-14 | 沙塔克实验室有限公司 | VSIG 8-based chimeric proteins |
ES2966835T3 (en) | 2017-06-22 | 2024-04-24 | CSL Behring Lengnau AG | Modulation of FVIII immunogenicity by truncated VWF |
US20210163986A1 (en) | 2017-08-09 | 2021-06-03 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
WO2019152692A1 (en) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing factor viii |
SG11202010767SA (en) * | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
BR112020023168A2 (en) * | 2018-05-18 | 2021-02-09 | Zhengzhou Gensciences Inc. | improved fviii fusion protein and use of it |
CN113166271A (en) * | 2018-05-18 | 2021-07-23 | 郑州晟斯生物科技有限公司 | Fusion polypeptide conjugates with extended half-life |
WO2020006576A1 (en) * | 2018-06-29 | 2020-01-02 | City Of Hope | Compositions and methods for treating autoimmune diseases |
EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
TW202039546A (en) | 2019-01-16 | 2020-11-01 | 美商巴克斯歐塔公司 | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
US10654911B1 (en) * | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
EP3736286A1 (en) | 2019-05-09 | 2020-11-11 | Biotest AG | Single chain factor viii molecule |
CN112175088B (en) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | FIX fusion proteins, conjugates and uses thereof |
WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
EP3785726A1 (en) * | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
JP2022546525A (en) * | 2019-09-02 | 2022-11-04 | ビオテスト・アクチエンゲゼルシャフト | Factor VIII protein with extended half-life |
WO2021067389A1 (en) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
WO2021126584A1 (en) * | 2019-12-19 | 2021-06-24 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
CN113087803B (en) * | 2021-05-12 | 2022-10-14 | 苏州大学附属第一医院 | Monoclonal antibody SZ176 for leader peptide of antihuman von willebrand factor and application thereof |
WO2023159135A2 (en) * | 2022-02-16 | 2023-08-24 | University Of Miami | Il-2 and tl1a fusion proteins and methods of use thereof |
Family Cites Families (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
ES8801674A1 (en) | 1985-04-12 | 1988-02-16 | Genetics Inst | Novel procoagulant proteins. |
KR910006424B1 (en) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | Method of manufacturing knitted briefs |
DE3785102T2 (en) | 1986-01-03 | 1993-07-22 | Genetics Inst | METHOD FOR PRODUCING FACTOR VIII: C TYPE PROTEINS. |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (en) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | FACTOR VIII: C-LIKE MOLECULE WITH COAGULATION ACTIVITY |
FR2619314B1 (en) | 1987-08-11 | 1990-06-15 | Transgene Sa | FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
SE465222C5 (en) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | A recombinant human factor VIII derivative and process for its preparation |
US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
SE504074C2 (en) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Protein preparation for subcutaneous, intramuscular or intradermal administration |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US20020019036A1 (en) * | 1996-12-13 | 2002-02-14 | Hans-Peter Schwarz | Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
WO1999051642A1 (en) | 1998-04-02 | 1999-10-14 | Genentech, Inc. | Antibody variants and fragments thereof |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
KR100887482B1 (en) | 1999-01-15 | 2009-03-10 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7829085B2 (en) * | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
ES2484966T3 (en) | 2000-04-12 | 2014-08-12 | Novozymes Biopharma Dk A/S | Albumin fusion proteins |
WO2001087922A2 (en) | 2000-05-16 | 2001-11-22 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
WO2002060919A2 (en) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
NZ530131A (en) * | 2001-06-15 | 2005-12-23 | Andre C | Gene therapy for hemophilia A |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
KR101271635B1 (en) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
WO2003074569A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
CN101143221A (en) | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | Central airway administration for systemic delivery of therapeutics |
PT1534335E (en) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Fcgammariib-specific antibodies and methods of use thereof |
AU2003275103A1 (en) | 2002-09-17 | 2004-04-08 | Diffusion Science, Inc. | Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres |
KR100960560B1 (en) | 2002-09-27 | 2010-06-03 | 젠코어 인코포레이티드 | Optimized fc variants and methods for their generation |
CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
US7041635B2 (en) * | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
EP2572732A1 (en) * | 2003-02-26 | 2013-03-27 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
KR100851263B1 (en) | 2003-02-28 | 2008-08-08 | 가부시키가이샤 구라레 | Curable resin composition |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP3552627A1 (en) | 2003-05-06 | 2019-10-16 | Bioverativ Therapeutics Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
RU2333223C2 (en) | 2003-08-12 | 2008-09-10 | Лайпоксен Текнолоджиз Лимитед | Aldehyde derivatives of sialic acid, methods of their obtainment, conjugates of aldehyde derivatives of sialic acid, and pharmaceutical composition based on them |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
EP2154157A3 (en) | 2004-01-12 | 2010-04-28 | Applied Molecular Evolution Inc. | FC region variants |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
EP2940043A1 (en) | 2004-07-15 | 2015-11-04 | Xencor, Inc. | Optimized fc variants |
US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
JP5022231B2 (en) * | 2004-12-27 | 2012-09-12 | バクスター・インターナショナル・インコーポレイテッド | Polymer-von Willebrand factor conjugate |
BRPI0614761A2 (en) | 2005-08-12 | 2009-05-19 | Human Genome Sciences Inc | albumin fusion proteins |
EP1996220B2 (en) * | 2006-03-06 | 2023-08-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
CN101415445A (en) * | 2006-03-31 | 2009-04-22 | 巴克斯特国际公司 | Pegylated factor VIII |
JP5800458B2 (en) | 2006-06-14 | 2015-10-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Fusion protein cleavable by proteolysis with blood clotting factor |
EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
CN101516388B (en) * | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | Glycosylation of peptides via O-linked glycosylation sequences |
EP2068905A4 (en) | 2006-09-14 | 2009-12-30 | Human Genome Sciences Inc | Albumin fusion proteins |
JP2010505874A (en) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | Purification method for polypeptide conjugates |
MX2009003470A (en) | 2006-10-04 | 2009-04-14 | Novo Nordisk As | Glycerol linked pegylated sugars and glycopeptides. |
EP1935430A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
EP2097096B1 (en) | 2006-12-22 | 2017-05-31 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
DK2147096T3 (en) * | 2007-04-13 | 2015-06-15 | Catalyst Biosciences Inc | Modified Factor VII polypeptides and uses thereof |
EP2162535A4 (en) | 2007-06-04 | 2011-02-23 | Novo Nordisk As | O-linked glycosylation using n-acetylglucosaminyl transferases |
KR101701080B1 (en) | 2007-06-21 | 2017-01-31 | 엑스엘-프로테인 게엠베하 | Biological active proteins having increased in vivo and/or vitro stability |
EP2185701A4 (en) * | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | Compositions and methods for modifying properties of biologically active polypeptides |
WO2009058446A1 (en) * | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
GB2467700A (en) | 2007-11-09 | 2010-08-11 | Baxter Int | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
JP5784907B2 (en) | 2007-12-28 | 2015-09-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Recombinant VWF formulation |
ES2298096B1 (en) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | PROCEDURE FOR OBTAINING A CONCENTRATE OF VON WILLEBRAND FACTOR OR FACTOR COMPLEX VIII / VON WILLEBRAND FACTOR AND USING THEMSELVES. |
ES2531464T3 (en) * | 2008-06-24 | 2015-03-16 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or its complexes with prolonged in vivo half-life |
DE102008032361A1 (en) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | The use of factor VIII and vWF or vWF-containing concentrates for the therapy of thrombocyte inhibitors induced coagulopathy |
CA2910512C (en) * | 2008-07-21 | 2020-10-27 | Apogenix Gmbh | Tnfsf single chain molecules |
CA2744340A1 (en) | 2008-11-24 | 2010-05-27 | Bayer Healthcare Llc | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
SI2393828T1 (en) * | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
CN102427823A (en) * | 2009-03-24 | 2012-04-25 | 拜耳医药保健有限公司 | Factor VIII variants and methods of use |
WO2010118435A2 (en) | 2009-04-10 | 2010-10-14 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (mmp-1) |
JP5839597B2 (en) | 2009-06-08 | 2016-01-06 | アムニクス オペレーティング インコーポレイテッド | Glucose-regulating polypeptide and methods for making and using the same |
DK2440241T3 (en) | 2009-06-08 | 2017-10-02 | Amunix Operating Inc | GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF |
WO2011020866A2 (en) * | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
PL2499165T3 (en) * | 2009-11-13 | 2017-04-28 | Grifols Therapeutics Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
RS56957B1 (en) * | 2009-12-06 | 2018-05-31 | Bioverativ Therapeutics Inc | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
JP2013519699A (en) * | 2010-02-16 | 2013-05-30 | ノヴォ ノルディスク アー/エス | Factor VIII fusion protein |
WO2011101242A1 (en) * | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
US8557961B2 (en) | 2010-04-02 | 2013-10-15 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
JP6148979B2 (en) | 2010-05-20 | 2017-06-14 | アラーガン、インコーポレイテッドAllergan,Incorporated | Degradable clostridial toxin |
US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
TW201217526A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
US11370827B2 (en) | 2012-01-12 | 2022-06-28 | Bioverativ Therapeutics Inc. | Chimeric factor VIII polypeptides and uses thereof |
DK2822577T3 (en) | 2012-02-15 | 2019-04-01 | Bioverativ Therapeutics Inc | RECOMBINANT FACTOR VIII PROTEINS |
EP3564260B1 (en) | 2012-02-15 | 2022-10-19 | Bioverativ Therapeutics Inc. | Factor viii compositions and methods of making and using same |
JP6603128B2 (en) | 2012-07-11 | 2019-11-06 | バイオベラティブ セラピューティクス インコーポレイテッド | Complex of factor VIII with XTEN and von Willebrand factor protein and uses thereof |
IL297611A (en) | 2013-06-28 | 2022-12-01 | Bioverativ Therapeutics Inc | Thrombin cleavable linker with xten and its uses thereof |
WO2014210547A1 (en) | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
MY192481A (en) | 2014-01-10 | 2022-08-23 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
-
2013
- 2013-01-12 US US14/371,948 patent/US11370827B2/en active Active
- 2013-01-12 ES ES13735649T patent/ES2753124T3/en active Active
- 2013-01-12 MX MX2014008512A patent/MX357403B/en active IP Right Grant
- 2013-01-12 CN CN201911267518.0A patent/CN111499761A/en active Pending
- 2013-01-12 HU HUE13735649A patent/HUE046396T2/en unknown
- 2013-01-12 RS RS20191424A patent/RS59670B1/en unknown
- 2013-01-12 CA CA2863328A patent/CA2863328A1/en active Pending
- 2013-01-12 DK DK13735649T patent/DK2804623T3/en active
- 2013-01-12 EA EA201491186A patent/EA028309B1/en not_active IP Right Cessation
- 2013-01-12 SI SI201331602T patent/SI2804623T1/en unknown
- 2013-01-12 CN CN201810666645.7A patent/CN109111526A/en active Pending
- 2013-01-12 NZ NZ626945A patent/NZ626945A/en unknown
- 2013-01-12 EP EP13735649.9A patent/EP2804623B1/en active Active
- 2013-01-12 SG SG11201403764XA patent/SG11201403764XA/en unknown
- 2013-01-12 LT LT13735649T patent/LT2804623T/en unknown
- 2013-01-12 WO PCT/US2013/021330 patent/WO2013106787A1/en active Application Filing
- 2013-01-12 KR KR1020147022369A patent/KR102212098B1/en active IP Right Grant
- 2013-01-12 PL PL13735649T patent/PL2804623T3/en unknown
- 2013-01-12 SG SG10201610193RA patent/SG10201610193RA/en unknown
- 2013-01-12 BR BR112014017165-3A patent/BR112014017165B1/en active IP Right Grant
- 2013-01-12 MY MYPI2018001814A patent/MY201293A/en unknown
- 2013-01-12 EA EA201791134A patent/EA035323B1/en unknown
- 2013-01-12 EP EP18211179.9A patent/EP3505179A1/en active Pending
- 2013-01-12 JP JP2014552353A patent/JP6255630B2/en active Active
- 2013-01-12 CN CN201911266598.8A patent/CN111499760A/en active Pending
- 2013-01-12 PT PT137356499T patent/PT2804623T/en unknown
- 2013-01-12 CN CN201380013452.7A patent/CN104271150A/en active Pending
- 2013-01-14 TW TW107124686A patent/TWI727187B/en active
- 2013-01-14 TW TW110112317A patent/TWI826778B/en active
- 2013-01-14 TW TW102101337A patent/TW201348253A/en unknown
-
2014
- 2014-06-30 IL IL233463A patent/IL233463B/en active IP Right Grant
- 2014-07-11 PH PH12014501602A patent/PH12014501602B1/en unknown
- 2014-07-15 CO CO14152717A patent/CO7010788A2/en unknown
-
2015
- 2015-04-01 HK HK15103334.2A patent/HK1202799A1/en unknown
-
2016
- 2016-05-04 AU AU2016202875A patent/AU2016202875B2/en active Active
-
2017
- 2017-11-15 JP JP2017219879A patent/JP6728121B2/en active Active
-
2018
- 2018-02-16 AU AU2018201163A patent/AU2018201163B2/en active Active
- 2018-06-13 PH PH12018501250A patent/PH12018501250A1/en unknown
- 2018-09-05 IL IL261632A patent/IL261632B/en unknown
-
2019
- 2019-10-22 HR HRP20191920TT patent/HRP20191920T1/en unknown
- 2019-11-07 CY CY20191101171T patent/CY1122509T1/en unknown
-
2020
- 2020-02-26 JP JP2020030737A patent/JP7113860B2/en active Active
-
2022
- 2022-05-27 US US17/826,932 patent/US20230011438A1/en active Pending
- 2022-07-26 JP JP2022118552A patent/JP7475613B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261632B (en) | Chimeric factor viii polypeptides and uses thereof | |
IL291571A (en) | Cx3cr1-binding polypeptides | |
HK1217731A1 (en) | Heterodimerized polypeptide | |
HK1210790A1 (en) | Modified factor polypeptides and uses thereof | |
EP2870170A4 (en) | Novel peptides and use thereof | |
EP2929045A4 (en) | Protein expression enhancing polypeptides | |
GB201220474D0 (en) | Polypeptides | |
GB201201100D0 (en) | Polypeptides and methods | |
SG11201500111VA (en) | Peptides and uses thereof | |
SG11201501646PA (en) | Peptides and their uses | |
HK1205747A1 (en) | Modified adiponectin polypeptides and their uses | |
EP2825548A4 (en) | Modified kisspeptin peptides and uses thereof | |
HK1201050A1 (en) | Polypeptides and their use | |
SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
HK1211042A1 (en) | Inflammation-enabling polypeptides and uses thereof | |
ZA201504462B (en) | TGFß-DERIVED POLYPEPTIDES AND USES THEREOF | |
GB201210303D0 (en) | Polypeptides and methods | |
GB201214769D0 (en) | Methodsa and peptides |